<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603616</url>
  </required_header>
  <id_info>
    <org_study_id>32871</org_study_id>
    <secondary_id>32871</secondary_id>
    <nct_id>NCT00603616</nct_id>
  </id_info>
  <brief_title>Induction of Clinical Response Using Rifaximin in Crohn's Disease</brief_title>
  <official_title>A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scott Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibiotics have been used to treat Crohn's disease symptoms with the best studied
      antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is
      FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is
      very poorly absorbed and over 97% of the drug taken orally is excreted in the feces.

      The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for
      the treatment of moderate to severe symptoms of Crohn's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory bowel disease (IBD) is a debilitating chronic inflammatory disease
      conventionally categorized into Crohn's disease (CD) and Ulcerative Colitis (UC). CD affects
      nearly 630,000 people in North America with up to 50,000 new people being diagnosed every
      year. It is a chronic debilitating disease characterized by abdominal pain, malnutrition,
      bloody diarrhea, fistula formation, intestinal perforations and strictures, and even
      extra-intestinal manifestations such as joint pains and skin rashes. Nearly 80% of people
      with CD will need surgical treatment at some point in their disease process. The majority of
      CD subjects are diagnosed in young adulthood thereby subjecting them to many decades of
      discomfort and medical intervention.

      Antibiotics have been used to treat CD with variable response rates. The basis for antibiotic
      therapy is that breakdown of the integrity of the mucosal barrier in the gastrointestinal
      (GI) tract leads to a heightened inflammatory response to commensurate luminal bacteria. By
      changing the composition or bacterial load in the intestinal lumen, it may be possible to
      alter the immune response. Ciprofloxacin (Cipro) and metronidazole (Flagyl) are the best
      studied antibiotics that have shown efficacy, but the effect is temporal and long term use
      can lead to serious side effects. Rifaximin is a recent FDA approved antibiotic with broad
      spectrum of activity, excellent safety profile, and minimal absorption from the GI tract.
      Open label and small studies in IBD subjects show response rates up to 80% in CD subjects.
      These studies were limited however in that they were not randomized placebo controlled
      trials.

      The investigators propose to conduct a randomized placebo controlled crossover trial of
      rifaximin in CD subjects to assess initial clinical response compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of rifaximin 550 mg bid compared to placebo in achieving clinical response in moderate to severe Crohn's Disease (CD) subjects as determined by a &gt; 100 point decrease in the Crohn's Disease Activity Index (CDAI)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of rifaximin compared to placebo at inducing clinical remission in CD subjects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety profile of rifaximin in subjects with active CD</measure>
    <time_frame>16 weeks for those subjects who do not cross over, 32 weeks for those who do cross over</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect rifaximin has on the quality of life in subjects with CD compared to placebo</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate if there are any clinical parameters which might predict response to rifaximin</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare mean changes in CDAI scores between rifaximin and placebo treated subjects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifaximin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Matching oral placebo pills to be taken twice daily for a total of 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Xifaxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, 18 to 80 years of age, inclusive, that can themselves provide
             written, informed consent and authorization of use of protected health information
             prior to any study-related procedures and who are, in the opinion of the
             investigator(s), likely to comply with all the requirements of the study

          -  Subjects must have a prior diagnosis of CD established by endoscopy and clinical
             parameters as determined by the investigator(s) for at least 3 months prior to
             randomization

          -  Subjects must be able to participate in all required follow-up visits and fill out all
             related documentation (e.g. symptom diary)

          -  Subjects currently with moderately active disease defined as a CDAI 250-450

          -  Concomitant medications:

               -  If subjects are taking sulfasalazine or 5-ASA products prior to entry, the dose
                  must be stable for at least 4 weeks prior to the randomization

               -  If subjects are on azathioprine, 6-mercaptopurine, or methotrexate, they will
                  have had to be on a stable dosage for at least 8 weeks

               -  Subjects are allowed to be on corticosteroids at a dose equivalent to 20 mg or
                  less of prednisone, IF the dose has been stable for a minimum of 2 weeks.
                  Steroids must be held stable throughout the induction portion of the study. The
                  maximum dose of budesonide must not exceed 9mg per day and must also have been
                  stable for a minimum of 2 weeks.

               -  No oral or intravenous antibiotics within 4 weeks prior to randomization

               -  No current or past use of biological treatment within 6 weeks of randomization
                  into study (e.g. infliximab)

               -  If subjects have previously been on any of the above products but are no longer
                  taking them, they should not have received any of the relevant therapeutic
                  products within 4 weeks prior to randomization

               -  No other experimental or non-FDA approved medications are allowed. If the subject
                  has previously been on an experimental therapy, they must have not received the
                  therapy within the prior 8 weeks prior to randomization

               -  Subjects on concomitant medications for CD will not be allowed to change dosages
                  during the study

          -  If subjects are at increased risk of colorectal cancer (defined as having an 8-year
             history of pan-colitis or 12 year history of left sided colitis), they will need to
             have undergone a colonoscopy with pan-colonic surveillance biopsies within 2 years of
             the screening visit. The biopsies must be negative for dysplasia

          -  Female or male subjects who are surgically sterilized or who are prepared to and agree
             to practice a double-barrier form of birth control from the screening visit through 30
             days (females) and 30 days (males), respectively, from the last dose of study
             medication. Females who are more than 12 months post-menopausal are also eligible to
             participate in the study

        Exclusion Criteria:

          -  Evidence of active infection which may include any of the following

               -  Febrile ( &gt; 38.5ÂºC)

               -  Positive blood culture within 2 weeks prior to randomization

               -  Evidence of toxic megacolon or abscess

               -  Positive stool culture for enteric pathogens, pathogenic ova or parasite, or a
                  positive assay for C. difficile toxin at screening

          -  Subjects with CDAI &gt; 450

          -  Any current use or use within the last 8 weeks of an investigational drug

          -  Current or past use (within past 12 wks) of biological treatment

          -  Current or use within the last 4 weeks of any oral or intravenous antibiotic

          -  Anticipated increased dosage of any medication to treat CD

          -  Anticipated need for surgery within 12 weeks

          -  Known obstructive diseases of the gastrointestinal system

          -  Medical conditions requiring in-patient hospitalization

          -  Proctocolectomy, total colectomy, ileostomy, or stoma

          -  Severe cardiopulmonary disease:

               -  Congestive heart failure (NYHA Class III or IV)

               -  Severe cardiovascular or peripheral vascular disease

               -  Myocardial infarction, percutaneous coronary intervention, or bypass surgery
                  within the past 6 months

          -  Significant liver disease:

               -  Levels of SGOT [AST], SGPT [ALT], or alkaline phosphatase &gt; 2.5x the upper limit
                  of the normal range for the laboratory performing test

               -  History of cirrhosis

          -  Renal insufficiency, defined as serum creatinine &gt; 150% of the upper limit of the
             normal range for the laboratory performing the test

          -  Abnormal hematology parameters defined as severe anemia with hemoglobin &lt; 8.5 g/dL
             and/or white blood cell count of &lt; 3,500/ul

          -  Malignancy within the past 2 years other than surgically cured skin carcinoma or
             cervical dysplasia (CIN I-II)

          -  History of dysplasia or carcinoma of the colon

          -  Pregnant, lactating, or planning to become pregnant during the course of the
             investigational study

          -  Known history of allergic reaction to rifaximin or allergy to any of the rifamycin
             antimicrobial agents (which include rifampin, rifabutin, and rifapentine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott D Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Scott Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Crohn disease</keyword>
  <keyword>Crohn's disease</keyword>
  <keyword>Rifaximin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

